A Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-61393215 in Healthy Japanese Adult Male Subjects
Latest Information Update: 01 Jul 2021
At a glance
- Drugs JNJ 61393215 (Primary)
- Indications Anxiety disorders; Major depressive disorder; Panic disorder
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Pharmaceutical KK
- 24 Jun 2021 Status changed from recruiting to completed.
- 12 Feb 2021 Status changed from not yet recruiting to recruiting.
- 20 Jan 2021 New trial record